Triple combination therapy group + Premixed insulin therapy group
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Oct 1, 2018 → Dec 20, 2019
NCT ID
NCT03700801About Triple combination therapy group + Premixed insulin therapy group
Triple combination therapy group + Premixed insulin therapy group is a approved stage product being developed by Sun Pharmaceutical for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT03700801. Target conditions include Type 2 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03700801 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus